Cambridge, Massachusetts-based biopharmaceutical company, Scholar Rock Holding Corporation, is devoted to pioneering medicines for the treatment of severe diseases where the activation of protein growth factors is key. Among its projects, the company's lead candidate Apitegromab, an inhibitor of the activation of latent myostatin, unequivocally passed Phase 3 clinical trials to treat spinal muscular atrophy. Furthermore, SRK-181, in its Phase 1 clinical trial stage, aims to cure resistant checkpoint inhibitor therapies for various cancer types, including anti-PD-1 or anti-PD-L1 antibody treatments. In addition, Scholar Rock Holding Corporation plans to create a range of innovative product candidates that can revolutionize the lives of patients with severe conditions, from neuromuscular disorders to iron-restricted anemia. The company also partnered with Gilead Sciences, Inc. to collaborate in developing specific inhibitors of transforming growth factor beta activation that target fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation remains committed to its mission of advancing the healthcare industry.
Scholar Rock's ticker is SRRK
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Scholar Rock
It is https://scholarrock.com/
Scholar Rock is in the Healthcare sector
Scholar Rock is in the Biotechnology industry
The following five companies are Scholar Rock's industry peers: